Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-08-24
2010-02-02
Kelly, Robert M. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S379000, C514S406000, C435S006120, C800S008000, C800S018000, C800S021000
Reexamination Certificate
active
07655700
ABSTRACT:
The present invention describes a transgenic mouse susceptible to neuromuscular disease. The present invention also includes methods for treatment of neuromuscular diseases by interfering with activity between androgen and androgen receptors exclusively in the muscle fibers.
REFERENCES:
patent: 2003/0049627 (2003-03-01), Nguyen et al.
patent: 2004/0087557 (2004-05-01), Steiner et al.
patent: 0703228 (2002-03-01), None
patent: 0703231 (2002-05-01), None
patent: 0806420 (2002-08-01), None
patent: 0651993 (2002-10-01), None
patent: 0747377 (2003-08-01), None
patent: 1255113 (2004-05-01), None
patent: 03/078463 (2003-09-01), None
Katsuno et al., 2003, Nature Medicine. 9:768-773.
Fishman et al., Brain. Res. Dev. Brain Res. 70:283-286.
Darrington et al., 2002, Molecular Neurosci. 13:2117-2120.
Garofalo et al.,1993, Neuromuscul. Disord. 3:195-199.
Cyproterone—dm.pdf. (http://www.cancercare.ns.ca/documents/Cyproterone—dm.pdf, by Cancer Care Nova Scotia, 2003).
Flutamide—BC Cancer Agency.pdf. (http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Flutamide.htm. by BC Cancer Agency, 2007).
Greenland et al., 2004, Int. Med. J. 34-279-286.
Balthazart et al, “Sexual differences in the Japanese quail: behavior, morphology, and intracellular metabolism of testosterone,” Gen Comp Endocrinol, vol. 51 (No. 2), p. 191-207/Abstract, (Aug. 1983).
Bingham et al, “Transgenic mice expressing and androgen receptor gene with an expanded CAG repeat in skeletal muscle,” American Journal of Human Genetics, vol. 57 (No. 4), p. A326, (1995).
Marron et al, “Androgen-induced neurite outgrowth is mediated by neuritin in motor neurones,” Journal of Neurochemistry, vol. 92, p. 10-20, (Jan. 2005).
Monks et al, “Increased androgen receptor expression in skeletal muscle fibers induces androgen-androgen dependent muscle pathology,” Society of Neuroscience Annual Meeting/Abstract, (Aug. 27, 2004).
Nakajima H, et al, “Tissue variability of androgen receptor gene in bulbospinal muscular atrophy-comparison of the number of CAG repeats between muscles and peripheral blood leukocytes,” Rinsho Shinkeigaku, vol. 33 (No. 10), p. 1103-1105, (Oct. 1993).
Simon et al, “Increased androgen receptor expression in skeletal muscle fibers leads to muscle pathology,”Society of Neuroscience Annual Meeting/Abstract, (Aug. 27, 2004).
Sugiura et al, “The involvement of skeletal muscle in neurodegeneration in jSOD1 mice,” Society of Neuroscience Annual Meeting/Abstract, (Aug. 27, 2004).
Szabo A et al, “Kennedy syndrome-bulbo-spinal muscular atrophy,” Ideggyogy Sz, vol. 55 (No. 9-10), p. 323-9, (Sep. 20, 2002).
Tanaka F, et al, Somatic mosaicism of expanded CAG trinucleotide repeat in spinal and bulbar muscular atrophy (SBMA). Nippon Rinsho, vol. 57, p. 862-868, (Apr. 1999).
Tanaka, et al, “Tissue-specific somatic mosaicism in spinal and bulbar muscular atrophy is dependent on CAG-repeat length and androgen receptor-gene expression level,” American Journal of Human Genetics, vol. 65, p. 966-973, (Oct. 1999).
Tuschl et al, “Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy,” Mol. Interv. vol. 2 (No. 3), p. 158-167, (Jun. 2002).
Walker et al, “Carbenoxoline increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation,” J. Clin Endorinol Metab, vol. 80 (No. 11), p. 3155-3159, (Nov. 1995).
Watanbe et al, “Mitotic and meiotic stability of the CAG repeat in the X-linked spinal and bulbar muscular atrophy gene,” Clinical Genetics, vol. 50, (No. 3), p. 133-137, (1996).
Breedlove Marc
Jordan Cynthia
Monks Douglas A.
Hiriyanna Kelaginamane T.
Kelly Robert M.
Michigan State University
Price Heneveld Cooper DeWitt & Litton LLP
LandOfFree
Transgenic mouse model and methods for treatment of neuro... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic mouse model and methods for treatment of neuro..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic mouse model and methods for treatment of neuro... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4217165